{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:38:51Z","timestamp":1763642331049},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 25% of the pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases are genetically unclassified. More thorough elucidation of the pathobiology of these genetically unclassified (\u2018B-other\u2019) cases may identify novel treatment options. We analyzed gene expression profiles of 572 pediatric BCP-ALL cases, representing all major ALL subtypes. High expression of <jats:italic>STAP1<\/jats:italic>, an adaptor protein downstream of the B-cell receptor (BCR), was identified in <jats:italic>BCR-ABL1<\/jats:italic>-like and non-<jats:italic>BCR-ABL1<\/jats:italic>-like B-other cases. Limma analysis revealed an association between high expression of <jats:italic>STAP1<\/jats:italic> and BCR signaling genes. However, <jats:italic>STAP1<\/jats:italic> expression and pre-BCR signaling were not causally related: cytoplasmic Ig\u03bc levels were not abnormal in cases with high levels of <jats:italic>STAP1<\/jats:italic> and stimulation of pre-BCR signaling did not induce <jats:italic>STAP1<\/jats:italic> expression. To elucidate the role of STAP1 in BCP-ALL survival, expression was silenced in two human BCP-ALL cell lines. Knockdown of <jats:italic>STAP1<\/jats:italic> did not reduce the proliferation rate or viability of these cells, suggesting that <jats:italic>STAP1<\/jats:italic> is not a likely candidate for precision medicines. Moreover, high expression of <jats:italic>STAP1<\/jats:italic> was not predictive for an unfavorable prognosis of <jats:italic>BCR-ABL1<\/jats:italic>-like and non-<jats:italic>BCR-ABL1<\/jats:italic>-like B-other cases. Remarkably, <jats:italic>DUX4<\/jats:italic>-rearrangements and intragenic <jats:italic>ERG<\/jats:italic> deletions, were enriched in cases harboring high expression of <jats:italic>STAP1<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/s41598-017-17704-4","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T16:44:24Z","timestamp":1515429864000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"8","author":[{"given":"Elisabeth M. P.","family":"Steeghs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Q.","family":"Hoogkamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith M.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quirine J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke","family":"Stalpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester A.","family":"de Groot-Kruseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"17704_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"CH Pui","year":"2013","unstructured":"Pui, C. H. & Evans, W. E. A 50-year journey to cure childhood acute lymphoblastic leukemia. Seminars in hematology 50, 185\u2013196, https:\/\/doi.org\/10.1053\/j.seminhematol.2013.06.007 (2013).","journal-title":"Seminars in hematology"},{"key":"17704_CR2","doi-asserted-by":"publisher","unstructured":"Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10, 125\u2013134, https:\/\/doi.org\/10.1016\/S1470-2045(08)70339-5 (2009).","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"17704_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England journal of medicine 360, 470\u2013480, https:\/\/doi.org\/10.1056\/NEJMoa0808253 (2009).","journal-title":"The New England journal of medicine"},{"key":"17704_CR4","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.18632\/oncotarget.13492","volume":"8","author":"JM Boer","year":"2017","unstructured":"Boer, J. M. et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget 8, 4618\u20134628, https:\/\/doi.org\/10.18632\/oncotarget.13492 (2017).","journal-title":"Oncotarget"},{"key":"17704_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.28","volume":"6","author":"T Imamura","year":"2016","unstructured":"Imamura, T. et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood cancer journal 6, e419, https:\/\/doi.org\/10.1038\/bcj.2016.28 (2016).","journal-title":"Blood cancer journal"},{"key":"17704_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The New England journal of medicine 371, 1005\u20131015, https:\/\/doi.org\/10.1056\/NEJMoa1403088 (2014).","journal-title":"The New England journal of medicine"},{"key":"17704_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer cell 22, 153\u2013166, https:\/\/doi.org\/10.1016\/j.ccr.2012.06.005 (2012).","journal-title":"Cancer cell"},{"key":"17704_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebjorn","year":"2016","unstructured":"Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nature communications 7, 11790, https:\/\/doi.org\/10.1038\/ncomms11790 (2016).","journal-title":"Nature communications"},{"key":"17704_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48, 569\u2013574, https:\/\/doi.org\/10.1038\/ng.3535 (2016).","journal-title":"Nat Genet"},{"key":"17704_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48, 1481\u20131489, https:\/\/doi.org\/10.1038\/ng.3691 (2016).","journal-title":"Nat Genet"},{"key":"17704_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert, R. C. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nature reviews. Immunology 13, 578\u2013591, https:\/\/doi.org\/10.1038\/nri3487 (2013).","journal-title":"Nature reviews. Immunology"},{"key":"17704_CR12","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/leu.2015.113","volume":"29","author":"J Eswaran","year":"2015","unstructured":"Eswaran, J. et al. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 29, 1623\u20131631, https:\/\/doi.org\/10.1038\/leu.2015.113 (2015).","journal-title":"Leukemia"},{"key":"17704_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573\u2013586, https:\/\/doi.org\/10.1016\/j.cell.2009.08.041 (2009).","journal-title":"Cell"},{"key":"17704_CR14","doi-asserted-by":"publisher","unstructured":"Herzog, S., Reth, M. & Jumaa, H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nature reviews. Immunology 9, 195\u2013205, https:\/\/doi.org\/10.1038\/nri2491 (2009).","DOI":"10.1038\/nri2491"},{"key":"17704_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1078155214561281","volume":"22","author":"CS Lee","year":"2016","unstructured":"Lee, C. S., Rattu, M. A. & Kim, S. S. A review of a novel, Bruton\u2019s tyrosine kinase inhibitor, ibrutinib. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners 22, 92\u2013104, https:\/\/doi.org\/10.1177\/1078155214561281 (2016).","journal-title":"Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners"},{"key":"17704_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cpt.85","volume":"97","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Zhang, L. L., Champlin, R. E. & Wang, M. L. Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies. Clinical pharmacology and therapeutics 97, 455\u2013468, https:\/\/doi.org\/10.1002\/cpt.85 (2015).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"17704_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","volume":"100","author":"A Wiestner","year":"2015","unstructured":"Wiestner, A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 100, 1495\u20131507, https:\/\/doi.org\/10.3324\/haematol.2014.119123 (2015).","journal-title":"Haematologica"},{"key":"17704_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","volume":"129","author":"E Kim","year":"2017","unstructured":"Kim, E. et al. Ibrutinib inhibits pre-BCR\u2009+\u2009B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129, 1155\u20131165, https:\/\/doi.org\/10.1182\/blood-2016-06-722900 (2017).","journal-title":"Blood"},{"key":"17704_CR19","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","volume":"125","author":"M Muschen","year":"2015","unstructured":"Muschen, M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood 125, 3688\u20133693, https:\/\/doi.org\/10.1182\/blood-2015-01-567842 (2015).","journal-title":"Blood"},{"key":"17704_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/leu.2016.9","volume":"30","author":"S Kohrer","year":"2016","unstructured":"Kohrer, S. et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia 30, 1246\u20131254, https:\/\/doi.org\/10.1038\/leu.2016.9 (2016).","journal-title":"Leukemia"},{"key":"17704_CR21","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer, A. et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122, 2622\u20132629, https:\/\/doi.org\/10.1182\/blood-2012-10-462358 (2013).","journal-title":"Blood"},{"key":"17704_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1074\/mcp.M700312-MCP200","volume":"7","author":"H Huang","year":"2008","unstructured":"Huang, H. et al. Defining the specificity space of the human SRC homology 2 domain. Mol Cell Proteomics 7, 768\u2013784, https:\/\/doi.org\/10.1074\/mcp.M700312-MCP200 (2008).","journal-title":"Mol Cell Proteomics"},{"key":"17704_CR23","doi-asserted-by":"publisher","first-page":"ra34","DOI":"10.1126\/scisignal.2000796","volume":"3","author":"T Kaneko","year":"2010","unstructured":"Kaneko, T. et al. Loops govern SH2 domain specificity by controlling access to binding pockets. Sci Signal 3, ra34, https:\/\/doi.org\/10.1126\/scisignal.2000796 (2010).","journal-title":"Sci Signal"},{"key":"17704_CR24","doi-asserted-by":"publisher","first-page":"11976","DOI":"10.1073\/pnas.96.21.11976","volume":"96","author":"K Ohya","year":"1999","unstructured":"Ohya, K. et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America 96, 11976\u201311981 (1999).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"17704_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1006\/bbrc.2001.6008","volume":"289","author":"K Yokohari","year":"2001","unstructured":"Yokohari, K. et al. Isoform-dependent interaction of BRDG1 with Tec kinase. Biochemical and biophysical research communications 289, 414\u2013420, https:\/\/doi.org\/10.1006\/bbrc.2001.6008 (2001).","journal-title":"Biochemical and biophysical research communications"},{"key":"17704_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbrc.2008.12.021","volume":"379","author":"K Stoecker","year":"2009","unstructured":"Stoecker, K. et al. Induction of STAP-1 promotes neurotoxic activation of microglia. Biochemical and biophysical research communications 379, 121\u2013126, https:\/\/doi.org\/10.1016\/j.bbrc.2008.12.021 (2009).","journal-title":"Biochemical and biophysical research communications"},{"key":"17704_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1006\/bbrc.2000.2223","volume":"268","author":"M Masuhara","year":"2000","unstructured":"Masuhara, M. et al. Molecular cloning of murine STAP-1, the stem-cell-specific adaptor protein containing PH and SH2 domains. Biochemical and biophysical research communications 268, 697\u2013703, https:\/\/doi.org\/10.1006\/bbrc.2000.2223 (2000).","journal-title":"Biochemical and biophysical research communications"},{"key":"17704_CR28","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874\u20134884, https:\/\/doi.org\/10.1182\/blood-2009-08-239681 (2010).","journal-title":"Blood"},{"key":"17704_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/leu.2013.277","volume":"28","author":"E Clappier","year":"2014","unstructured":"Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70\u201377, https:\/\/doi.org\/10.1038\/leu.2013.277 (2014).","journal-title":"Leukemia"},{"key":"17704_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/leu.2013.282","volume":"28","author":"M Zaliova","year":"2014","unstructured":"Zaliova, M. et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 28, 182\u2013185, https:\/\/doi.org\/10.1038\/leu.2013.282 (2014).","journal-title":"Leukemia"},{"key":"17704_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","volume":"8","author":"YF Liu","year":"2016","unstructured":"Liu, Y. F. et al. Genomic Profiling of Adult and Pediatric B-cell Acute LymphoblasticLeukemia. EbioMedicine 8, 173\u2013183, https:\/\/doi.org\/10.1016\/j.ebiom.2016.04.038 (2016).","journal-title":"EbioMedicine"},{"key":"17704_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/ng.3466","volume":"48","author":"X Zhou","year":"2016","unstructured":"Zhou, X. et al. Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet 48, 4\u20136, https:\/\/doi.org\/10.1038\/ng.3466 (2016).","journal-title":"Nat Genet"},{"key":"17704_CR33","first-page":"2285","volume":"6","author":"ES Reddy","year":"1991","unstructured":"Reddy, E. S. & Rao, V. N. erg, an ets-related gene, codes for sequence-specific transcriptional activators. Oncogene 6, 2285\u20132289 (1991).","journal-title":"Oncogene"},{"key":"17704_CR34","doi-asserted-by":"publisher","unstructured":"Loughran, S. J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 9, 810-819, https:\/\/doi.org\/10.1038\/ni.1617 (2008).","DOI":"10.1038\/ni.1617"},{"key":"17704_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0294-146","volume":"6","author":"PH Sorensen","year":"1994","unstructured":"Sorensen, P. H. et al. A second Ewing\u2019s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6, 146\u2013151, https:\/\/doi.org\/10.1038\/ng0294-146 (1994).","journal-title":"Nat Genet"},{"key":"17704_CR36","doi-asserted-by":"crossref","unstructured":"Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8, 497\u2013511, doi:nrc2402 [pii]10.1038\/nrc2402 (2008).","DOI":"10.1038\/nrc2402"},{"key":"17704_CR37","doi-asserted-by":"publisher","first-page":"9234","DOI":"10.1200\/JCO.2005.03.6137","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci, G. et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23, 9234\u20139242, https:\/\/doi.org\/10.1200\/JCO.2005.03.6137 (2005).","journal-title":"J Clin Oncol"},{"key":"17704_CR38","doi-asserted-by":"publisher","unstructured":"van Geel, M. et al. Genomic analysis of human chromosome 10q and 4q telomeres suggests a common origin. Genomics 79, 210\u2013217, https:\/\/doi.org\/10.1006\/geno.2002.6690S0888754302966905 (2002).","DOI":"10.1006\/geno.2002.6690S0888754302966905"},{"key":"17704_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.nmd.2007.04.002","volume":"17","author":"V Kowaljow","year":"2007","unstructured":"Kowaljow, V. et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscular disorders: NMD 17, 611\u2013623, https:\/\/doi.org\/10.1016\/j.nmd.2007.04.002 (2007).","journal-title":"Neuromuscular disorders: NMD"},{"key":"17704_CR40","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Den Boer","year":"2003","unstructured":"Den Boer, M. L. et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21, 3262\u20133268, https:\/\/doi.org\/10.1200\/JCO.2003.11.031 (2003).","journal-title":"J Clin Oncol"},{"key":"17704_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/pbc.24273","volume":"60","author":"G Escherich","year":"2013","unstructured":"Escherich, G., Zimmermann, M. & Janka-Schaub, G. & CoALL study group. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer 60, 254\u2013257, https:\/\/doi.org\/10.1002\/pbc.24273 (2013).","journal-title":"Pediatr Blood Cancer"},{"key":"17704_CR42","doi-asserted-by":"publisher","unstructured":"Veerman, A. J. et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004). Lancet Oncol 10, 957-966, doi:S1470-2045(09)70228-1 [pii] https:\/\/doi.org\/10.1016\/S1470-2045(09)70228-1 (2009).","DOI":"10.1016\/S1470-2045(09)70228-1"},{"key":"17704_CR43","doi-asserted-by":"publisher","unstructured":"Escherich, G. et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 96, 854-862, https:\/\/doi.org\/10.3324\/haematol.2010.039735 (2011).","DOI":"10.3324\/haematol.2010.039735"},{"key":"17704_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/sj.leu.2402489","volume":"16","author":"WA Kamps","year":"2002","unstructured":"Kamps, W. A. et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991\u20131996). Leukemia 16, 1099\u20131111, https:\/\/doi.org\/10.1038\/sj.leu.2402489 (2002).","journal-title":"Leukemia"},{"key":"17704_CR45","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters, R. et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 34, 2591\u20132601, https:\/\/doi.org\/10.1200\/JCO.2015.64.6364 (2016).","journal-title":"J Clin Oncol"},{"key":"17704_CR46","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","volume":"100","author":"JM Boer","year":"2015","unstructured":"Boer, J. M. et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica 100, e261\u2013264, https:\/\/doi.org\/10.3324\/haematol.2014.117424 (2015).","journal-title":"Haematologica"},{"key":"17704_CR47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/bioinformatics\/btm030","volume":"23","author":"MA van de Wiel","year":"2007","unstructured":"van de Wiel, M. A. et al. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23, 892\u2013894, https:\/\/doi.org\/10.1093\/bioinformatics\/btm030 (2007).","journal-title":"Bioinformatics"},{"key":"17704_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-401","volume":"10","author":"BP van Houte","year":"2009","unstructured":"van Houte, B. P., Binsl, T. W., Hettling, H., Pirovano, W. & Heringa, J. CGHnormaliter: an iterative strategy to enhance normalization of array CGH data with imbalanced aberrations. BMC genomics 10, 401, https:\/\/doi.org\/10.1186\/1471-2164-10-401 (2009).","journal-title":"BMC genomics"},{"key":"17704_CR49","unstructured":"Gray, R. J. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-6. http:\/\/CRAN.R-project.org\/package=cmprsk (2013)."},{"key":"17704_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC De Wreede","year":"2011","unstructured":"De Wreede, L. C., Fiocco, M. & Putter, H. mstate: An R Package for the Analysis of Competing Risks and Multi-State Models. J Stat Softw 38, 1\u201330 (2011).","journal-title":"J Stat Softw"},{"key":"17704_CR51","unstructured":"Therneau, T. A Package for Survival Analysis in S. R package version 2.36-12 (2012)."},{"key":"17704_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. Journal of molecular biology 215, 403\u2013410, https:\/\/doi.org\/10.1016\/S0022-2836(05)80360-2 (1990).","journal-title":"Journal of molecular biology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17704-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:57:46Z","timestamp":1671584266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17704-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["17704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17704-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"11 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"693"}}